Cathay Biotech Past Earnings Performance
Past criteria checks 3/6
Cathay Biotech's earnings have been declining at an average annual rate of -4%, while the Chemicals industry saw earnings growing at 4.9% annually. Revenues have been growing at an average rate of 9.4% per year. Cathay Biotech's return on equity is 2.6%, and it has net margins of 14.4%.
Key information
-4.0%
Earnings growth rate
-6.6%
EPS growth rate
| Chemicals Industry Growth | 12.1% |
| Revenue growth rate | 9.4% |
| Return on equity | 2.6% |
| Net Margin | 14.4% |
| Next Earnings Update | 13 Nov 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Cathay Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,764 | 398 | 238 | 232 |
| 30 Jun 24 | 2,528 | 372 | 227 | 203 |
| 31 Mar 24 | 2,293 | 414 | 198 | 184 |
| 31 Dec 23 | 2,114 | 367 | 215 | 189 |
| 30 Sep 23 | 2,169 | 381 | 235 | 179 |
| 30 Jun 23 | 2,183 | 459 | 256 | 187 |
| 31 Mar 23 | 2,285 | 436 | 270 | 199 |
| 31 Dec 22 | 2,441 | 553 | 239 | 188 |
| 30 Sep 22 | 2,447 | 605 | 207 | 184 |
| 30 Jun 22 | 2,517 | 619 | 188 | 164 |
| 31 Mar 22 | 2,538 | 628 | 182 | 145 |
| 31 Dec 21 | 2,363 | 595 | 181 | 134 |
| 30 Sep 21 | 2,099 | 612 | 143 | 118 |
| 30 Jun 21 | 1,839 | 564 | 147 | 99 |
| 31 Mar 21 | 1,579 | 481 | 144 | 97 |
| 31 Dec 20 | 1,497 | 458 | 146 | 84 |
| 30 Sep 20 | 1,482 | 428 | 181 | 70 |
| 30 Jun 20 | 1,601 | 432 | 203 | 41 |
| 31 Mar 20 | 1,722 | 475 | 258 | 105 |
| 31 Dec 19 | 1,916 | 479 | 212 | 90 |
| 31 Dec 18 | 1,757 | 466 | 185 | 86 |
| 31 Dec 17 | 1,363 | 333 | 131 | 65 |
| 31 Dec 16 | 929 | 145 | 105 | 38 |
Quality Earnings: 688065 has high quality earnings.
Growing Profit Margin: 688065's current net profit margins (14.4%) are lower than last year (17.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688065's earnings have declined by 4% per year over the past 5 years.
Accelerating Growth: 688065's earnings growth over the past year (4.4%) exceeds its 5-year average (-4% per year).
Earnings vs Industry: 688065 earnings growth over the past year (4.4%) exceeded the Chemicals industry -5.3%.
Return on Equity
High ROE: 688065's Return on Equity (2.6%) is considered low.